3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
5
Recurrence
2
Esophageal Neoplasms
2
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Etoposide
154
Carboplatin
142
Cisplatin
104
Topotecan
74
durvalumab
48
atezolizumab
46
Irinotecan
44
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
29
anlotinib
23
PM 01183
22
Gemcitabine
21
Drug Therapy
20
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Bevacizumab
13
amrubicin
11
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
11
rovalpituzumab tesirine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Small Cell Lung Carcinoma
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts